🔎 Trials Near Me

Home › Overweight › Michigan

Pag-aaral pangklinika para sa Overweight sa Michigan

19 pag-aaral para sa Overweight ang naghahanap ng mga kalahok sa mga site sa Michigan.

Mga Lungsod sa Michigan

Opisyal na teksto ng pag-aaral (English)

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

  • Profound Research, Farmington Hills
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07837973

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

  • Great Lakes Research Group, Inc., Bay City
  • Great Lakes Research Institute, Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07794579

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

  • Northern Pines Hlth Ctr, PC, Buckley
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07720271

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

  • Aa Mrc Llc, Flint
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07595549

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

  • Helen Devos Childrens' Hospital - PIN, Grand Rapids
Nagre-recruitPhase 3
Edad 6 hanggang 17 · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06672549

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

  • Headlands Research - Detroit, Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07589608

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  • Great Lakes Research Institute, Southfield
  • Revive Research Institute, Inc., Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07392190

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

  • Revive Research Institute, Inc., Southfield
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07369011

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Farmington Hills
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07784270

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07321886

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Southfield
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT07743450

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

  • Headlands Research - Detroit, Southfield
  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 8, 2026 · NCT06143956

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

  • David Fivenson, MD, PLC, Ann Arbor
  • The Derm Institute of West Michigan, Caledonia
Nagre-recruitPhase 4
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT06857942

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  • Kailera Clinical Site, Farmington Hills
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

  • Headlands Research - Detroit, Southfield
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Set 3, 2026 · NCT07684235

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  • Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research Division, Troy
Nagre-recruitPhase 3
Edad 18 hanggang 99 · Lahat ng kasarian · Na-update Ago 27, 2026 · NCT07575399

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

  • Research Site, Troy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT07784725

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

  • Arcturus Healthcare, PLC., Troy
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

  • ACCOMPLISH-1 Research Site, Ann Arbor
Nagre-recruitPhase 3
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Ago 10, 2026 · NCT07654361

Mula sa ClinicalTrials.gov, na-kuha noong Set 30, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.